Laboratory of Medical Biology-Genetics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece.
Int J Mol Sci. 2024 Mar 29;25(7):3812. doi: 10.3390/ijms25073812.
Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM), suggesting a crucial interplay between the gut-brain axis. Glucagon-like peptide-1 receptor (GLP-1R) agonists, known for their use in T2DM treatment, are currently extensively studied as novel PD modifying agents. For this narrative review article, we searched PubMed and Scopus databases for peer-reviewed research, review articles and clinical trials regarding GLP-1R agonists and PD published in the English language with no time restrictions. We also screened the references of the selected articles for possible additional articles in order to include most of the key recent evidence. Many data on animal models and preclinical studies show that GLP1-R agonists can restore dopamine levels, inhibit dopaminergic loss, attenuate neuronal degeneration and alleviate motor and non-motor features of PD. Evidence from clinical studies is also very promising, enhancing the possibility of adding GLP1-R agonists to the current armamentarium of drugs available for PD treatment.
帕金森病（PD）是最常见的神经退行性疾病之一。最近的数据强调了神经退行性疾病之间的相似性，包括 PD 和 2 型糖尿病（T2DM），这表明肠道-大脑轴之间存在着至关重要的相互作用。胰高血糖素样肽-1 受体（GLP-1R）激动剂，因其在 T2DM 治疗中的应用而闻名，目前作为新型 PD 修饰剂正在被广泛研究。在这篇叙述性综述文章中，我们在 PubMed 和 Scopus 数据库中搜索了发表在英文期刊上、无时间限制的关于 GLP-1R 激动剂和 PD 的同行评审研究、综述文章和临床试验。我们还筛选了选定文章的参考文献，以纳入可能的其他关键近期证据。许多关于动物模型和临床前研究的数据表明，GLP1-R 激动剂可以恢复多巴胺水平，抑制多巴胺能损失，减轻神经元变性，并缓解 PD 的运动和非运动特征。来自临床研究的证据也非常有希望，增加了将 GLP1-R 激动剂添加到目前 PD 治疗药物中的可能性。
